SV2012004192A - Nuevo uso antitumoral de cabazitaxel - Google Patents

Nuevo uso antitumoral de cabazitaxel

Info

Publication number
SV2012004192A
SV2012004192A SV2012004192A SV2012004192A SV2012004192A SV 2012004192 A SV2012004192 A SV 2012004192A SV 2012004192 A SV2012004192 A SV 2012004192A SV 2012004192 A SV2012004192 A SV 2012004192A SV 2012004192 A SV2012004192 A SV 2012004192A
Authority
SV
El Salvador
Prior art keywords
cabazitaxel
new antitumoral
prostate cancer
antitumoral use
treatment
Prior art date
Application number
SV2012004192A
Other languages
English (en)
Inventor
Sunil Gupta
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2012004192(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of SV2012004192A publication Critical patent/SV2012004192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE A UN COMPUESTO DE FÓRMULA (I): QUE PUEDE ESTAR EN FORMA DE BASE O EN FORMA DE HIDRATO O UN SOLVATO, EN COMBINACIÓN CON PREDNISONA O PREDNISOLONA, PARA SU USO COMO MEDICAMENTO EN EL TRATAMIENTO DEL CÁNCER DE PRÓSTATA, PARTICULARMENTE CÁNCER METASTÁSICO DE PRÓSTATA, ESPECIALMENTE PARA PACIENTES QUE NO SIGUEN UN TRATAMIENTO BASADO EN TAXANO
SV2012004192A 2009-10-29 2012-04-27 Nuevo uso antitumoral de cabazitaxel SV2012004192A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US25616009P 2009-10-29 2009-10-29
US29390310P 2010-01-11 2010-01-11
US35588810P 2010-06-17 2010-06-17
US35583410P 2010-06-17 2010-06-17
US36992910P 2010-08-02 2010-08-02
US38393310P 2010-09-17 2010-09-17
US38996910P 2010-10-05 2010-10-05

Publications (1)

Publication Number Publication Date
SV2012004192A true SV2012004192A (es) 2012-08-23

Family

ID=43567614

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2012004192A SV2012004192A (es) 2009-10-29 2012-04-27 Nuevo uso antitumoral de cabazitaxel

Country Status (31)

Country Link
US (8) US8927592B2 (es)
EP (1) EP2493466B1 (es)
JP (2) JP5566466B2 (es)
KR (1) KR101712231B1 (es)
CN (1) CN102770131A (es)
AR (1) AR078824A1 (es)
AU (4) AU2010310986A1 (es)
BR (1) BR112012011457A2 (es)
CA (1) CA2779009A1 (es)
CR (1) CR20120204A (es)
DK (1) DK2493466T3 (es)
EA (1) EA024186B1 (es)
EC (1) ECSP12011836A (es)
ES (1) ES2862340T3 (es)
GT (1) GT201200123A (es)
IL (3) IL219443A0 (es)
MA (1) MA33767B1 (es)
MX (1) MX336339B (es)
MY (1) MY164086A (es)
NI (1) NI201200071A (es)
PE (1) PE20121429A1 (es)
PH (1) PH12012500848A1 (es)
PL (1) PL2493466T3 (es)
PT (1) PT2493466T (es)
SG (1) SG10201810928SA (es)
SV (1) SV2012004192A (es)
TN (1) TN2012000188A1 (es)
TW (2) TWI654975B (es)
UY (1) UY32987A (es)
WO (1) WO2011051894A1 (es)
ZA (1) ZA201203123B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
EP2493466B1 (en) 2009-10-29 2021-03-10 Sanofi Mature IP Novel antitumoral use of cabazitaxel
CN103764637A (zh) * 2011-04-12 2014-04-30 普拉斯化学品有限公司 卡巴他赛的固态形式及其制备方法
CN102503913B (zh) * 2011-10-20 2014-03-26 江苏红豆杉生物科技股份有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
EP2791122B1 (en) * 2011-12-13 2019-01-23 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same
US9403785B2 (en) * 2012-01-03 2016-08-02 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
EP2880021A4 (en) 2012-07-31 2015-06-17 Yung Shin Pharm Ind Co Ltd AMORPHIC CABACITAXEL
TW201438714A (zh) * 2013-03-04 2014-10-16 Aventis Pharma Sa 卡巴他賽（ｃａｂａｚｉｔａｘｅｌ）及其治療轉移性前列腺癌之用途
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
ES2817331T3 (es) * 2015-02-17 2021-04-07 Univ Erasmus Med Ct Rotterdam Uso del cabazitaxel en el tratamiento del cáncer de próstata
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
EP3509569A1 (en) 2016-09-07 2019-07-17 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
US10195214B2 (en) * 2017-03-01 2019-02-05 Corcept Therapeutics, Inc. Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
WO2018187786A1 (en) * 2017-04-07 2018-10-11 La Jolla Institute For Allergy And Immunology Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof
US20250017891A1 (en) * 2023-07-04 2025-01-16 Twi Pharmaceuticals, Inc. Pharmaceutical composition comprising cabazitaxel prodrug-cyclodextrin inclusion complex, and applications thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5005588A (en) 1989-10-13 1991-04-09 David Rubin Method for increasing tumor sensitivity to chemotherapy
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
ZA94128B (en) 1993-02-01 1994-08-19 Univ New York State Res Found Process for the preparation of taxane derivatives and betalactam intermediates therefor
FR2732340B1 (fr) 1995-03-27 1997-04-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
FR2745814B1 (fr) 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
US6346543B1 (en) 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
MXPA01001721A (es) 1998-08-20 2005-06-03 Aventis Pharma Sa Nuevo uso de derivados de taxoide.
US6403634B1 (en) 1999-01-13 2002-06-11 Aventis Pharma S.A. Use of taxoid derivatives
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
EP1493556B1 (de) 2003-07-02 2005-08-24 Scheuten Glasgroep Verfahren zur Herstellung einer Brandschutzverglasung
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CN102747141A (zh) 2004-12-08 2012-10-24 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
EP1700596A1 (en) 2005-03-09 2006-09-13 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2177630A1 (en) * 2008-10-02 2010-04-21 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA201171195A8 (ru) 2009-03-30 2014-08-29 Серулин Фарма Инк. Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
CA2939165A1 (en) 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
EP2493466B1 (en) * 2009-10-29 2021-03-10 Sanofi Mature IP Novel antitumoral use of cabazitaxel
US8686165B2 (en) 2009-11-04 2014-04-01 Emcure Pharmaceuticals Limited Process for preparation of taxane derivatives
EP2503888A4 (en) 2009-11-23 2015-07-29 Cerulean Pharma Inc POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION
EP2556166A1 (en) 2010-04-08 2013-02-13 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2011130317A2 (en) 2010-04-13 2011-10-20 Amplyx Pharmaceuticals Inc. Therapeutic agents having reduced toxicity
EP2558109A4 (en) 2010-04-16 2014-09-24 Bellicum Pharmaceuticals Inc METHOD FOR TREATING HARD TUMORS
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Also Published As

Publication number Publication date
EA201270606A1 (ru) 2013-01-30
JP6182510B2 (ja) 2017-08-16
US8927592B2 (en) 2015-01-06
ZA201203123B (en) 2013-06-26
US10716777B2 (en) 2020-07-21
US20210169843A1 (en) 2021-06-10
AU2017232227B2 (en) 2019-06-06
NI201200071A (es) 2012-08-20
TW201611831A (en) 2016-04-01
BR112012011457A2 (pt) 2016-05-03
US20150118182A1 (en) 2015-04-30
US20180125810A1 (en) 2018-05-10
IL267583A (en) 2019-08-29
TWI533866B (zh) 2016-05-21
MY164086A (en) 2017-11-30
CA2779009A1 (en) 2011-05-05
KR101712231B1 (ko) 2017-03-03
US20200155497A1 (en) 2020-05-21
EP2493466B1 (en) 2021-03-10
WO2011051894A1 (en) 2011-05-05
AU2019203514A1 (en) 2019-06-06
JP2014196323A (ja) 2014-10-16
TW201127374A (en) 2011-08-16
TWI654975B (zh) 2019-04-01
JP2013509394A (ja) 2013-03-14
IL219443A0 (en) 2012-06-28
CR20120204A (es) 2012-07-04
MX2012005030A (es) 2012-12-05
US10583110B2 (en) 2020-03-10
KR20120093986A (ko) 2012-08-23
EA024186B1 (ru) 2016-08-31
PH12012500848A1 (en) 2016-02-08
AU2017232227A1 (en) 2017-10-12
SG10201810928SA (en) 2019-01-30
CN102770131A (zh) 2012-11-07
TN2012000188A1 (en) 2013-12-12
AR078824A1 (es) 2011-12-07
PL2493466T3 (pl) 2021-11-15
JP5566466B2 (ja) 2014-08-06
MA33767B1 (fr) 2012-11-01
AU2010310986A1 (en) 2012-06-14
US20240139146A1 (en) 2024-05-02
AU2016200598A1 (en) 2016-02-25
IL250254A0 (en) 2017-03-30
MX336339B (es) 2016-01-14
UY32987A (es) 2011-05-31
GT201200123A (es) 2013-11-07
EP2493466A1 (en) 2012-09-05
US20120301425A1 (en) 2012-11-29
US12453712B2 (en) 2025-10-28
PE20121429A1 (es) 2012-11-06
DK2493466T3 (da) 2021-04-26
PT2493466T (pt) 2021-03-29
US20150104411A1 (en) 2015-04-16
US20190151278A1 (en) 2019-05-23
ES2862340T3 (es) 2021-10-07
ECSP12011836A (es) 2012-07-31

Similar Documents

Publication Publication Date Title
ECSP12011836A (es) Nuevo uso antitumoral de cabazitaxel
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
ECSP14013325A (es) Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr)
GB201209613D0 (en) New compounds
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
EA201171367A1 (ru) Винилиндазолильные соединения
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
DOP2012000250A (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
CO6341625A2 (es) Derivados de indol como agentes anticáncer
AR067769A1 (es) Derivado de ditiazol para el tratamiento del cancer
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
CO6761366A2 (es) Composiciones farmacéuticas para el tratamiento de glioma maligno
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
ECSP11011550A (es) Procedimientos de uso del factor liberador de corticotropina para eltratamiento de cáncer
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
CO6531492A2 (es) Nuevo uso antitumoral de cabazitaxel
UY32974A (es) Derivados de aminotiazol